There are 3397 resources available
1355P - Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
Presenter: Marta Brambilla
Session: Poster session 19
1356P - 10-year survivors treated with tyrosine kinase inhibitor for advanced non-small cell lung cancer
Presenter: Yu Tanaka
Session: Poster session 19
1357P - Bevacizumab improved prognosis for advanced EGFR mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy
Presenter: YuanLiang Zhou
Session: Poster session 19
1358P - Safety of tepotinib + EGFR TKI (osimertinib or gefitinib) in patients with EGFRm NSCLC
Presenter: Ernest Nadal
Session: Poster session 19
1359P - Relationship between tumor TP53 gene mutation, circulating anti-p53 antibodies and response to first-line osimertinib in EGFR-mutated NSCLC patients
Presenter: Marc Denis
Session: Poster session 19
1361P - Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A
Presenter: Shirish Gadgeel
Session: Poster session 19
1362P - Association of baseline (BL) anaplastic lymphoma kinase (ALK) fusion detected by circulating tumor DNA (ctDNA) with clinical features and outcomes in the phase III ALTA-3 trial
Presenter: Charu Aggarwal
Session: Poster session 19
1363P - Genomic heterogeneity of ALK rearrangements and acquired resistance pathways in ALK+ Advanced non-small cell lung cancer (NSCLC) treated with upfront alectinib: Preliminary results of GALILEO project
Presenter: Emanuele Vita
Session: Poster session 19
1364P - ctDNA analysis of SAF-189s efficacy in ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Jin-Ji Yang
Session: Poster session 19